Insulet Corporation Stock

Equities

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
166.3 USD -3.73% Intraday chart for Insulet Corporation -6.28% -23.38%
Sales 2024 * 1.96B Sales 2025 * 2.32B Capitalization 11.64B
Net income 2024 * 215M Net income 2025 * 279M EV / Sales 2024 * 6.14 x
Net Debt 2024 * 392M Net Debt 2025 * 81.38M EV / Sales 2025 * 5.05 x
P/E ratio 2024 *
56.5 x
P/E ratio 2025 *
44.1 x
Employees 3,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.69%
More Fundamentals * Assessed data
Dynamic Chart
US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady MT
Insulet Names Ana Maria Chadwick Finance Chief MT
Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024 CI
Insulet Corporation Announces Chief Financial Officer Changes CI
3M Board Approves Healthcare Unit Spinoff -- Update DJ
Transcript : Insulet Corporation - Special Call
Insulet Says Trial Shows Omnipod 5 Insulin Delivery System Superior to Pump Therapy MT
Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) CI
Transcript : Insulet Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:35 AM
Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes CI
Stocks in motion: Alphabet drops as Microsoft signs another AI partnership Our Logo
Barclays Trims Insulet Price Target to $213 From $214, Maintains Equal Weight Rating MT
Insulet forecasts weak annual revenue growth; shares drop RE
Insulet Q4 Adjusted Earnings, Revenue Increase; Q1, 2024 Revenue Outlook Set MT
Transcript : Insulet Corporation, Q4 2023 Earnings Call, Feb 22, 2024
More news

Latest transcript on Insulet Corporation

1 day-3.73%
1 week-6.28%
Current month-3.00%
1 month+0.24%
3 months-17.24%
6 months+17.60%
Current year-23.38%
More quotes
1 week
165.10
Extreme 165.1
178.49
1 month
161.68
Extreme 161.68
180.01
Current year
160.84
Extreme 160.84
217.46
1 year
125.82
Extreme 125.82
335.91
3 years
125.82
Extreme 125.82
335.91
5 years
81.82
Extreme 81.82
335.91
10 years
23.94
Extreme 23.94
335.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-07-30
Founder 54 13-12-31
Director of Finance/CFO 49 19-04-28
Members of the board TitleAgeSince
Director/Board Member 57 17-08-09
Chairman 60 14-08-13
Director/Board Member 64 22-02-03
More insiders
Date Price Change Volume
24-04-17 166.3 -3.73% 688,850
24-04-16 172.7 -0.71% 656,034
24-04-15 173.9 -0.73% 818,337
24-04-12 175.2 -2.47% 680,529
24-04-11 179.6 +1.26% 696,787

Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT

More quotes
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (95.6%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (4.4%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). By the end of 2022, the group will have 2 production sites located in the United States and in China. The United States accounts for 72.2% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
166.3 USD
Average target price
236.3 USD
Spread / Average Target
+42.11%
Consensus